Rein Therapeutics Announces Publication of New Translational Data in iScience on Company's Novel Therapy for Idiopathic Pulmonary Fibrosis

Core Insights - Rein Therapeutics announced the publication of novel data on its lead drug candidate, LTI-03, demonstrating its potential in treating idiopathic pulmonary fibrosis (IPF) [1][2] Urgent Need - IPF affects approximately 100,000 people in the U.S. and over 70,000 in the U.K., with a median survival of just 3-5 years from diagnosis, highlighting the urgent need for effective treatments [4] - The global market for IPF treatments is projected to exceed $11 billion by 2031, indicating significant commercial potential [4] Study Findings - The study utilized real lung tissue from IPF patients, showing that LTI-03 reduced multiple scarring pathways and lowered collagen production without causing cell damage, unlike the standard-of-care drug nintedanib [7] - LTI-03 demonstrated anti-fibrotic activity, reinforcing its potential as a new therapy for IPF [2][7] Next Steps - Rein Therapeutics received regulatory approval from the U.K.'s MHRA to initiate the Phase 2 RENEW trial of LTI-03, which will evaluate safety and changes in lung function in up to 120 patients, with initial data expected in 2026 [5]